Doxazosin

• CAT Number: I004756
• CAS Number: 74191-85-8
• Molecular Formula: C23H25N5O5
• Molecular Weight: 451.48
• Purity: ≥95%
• Synonyms: UK 33274; UK-33274; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
• Target: Adrenergic Receptor
• Solubility: DMSO 15 mg/ mL; Water <1 mg/ mL; Ethanol <1 mg/mL
• Storage: Store at -20°C
• InChI: 1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)
• InChIKey: RUZYUOTYCVRMRZ-UHFFFAOYSA-N
• SMILES: COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC

Doxazosin (CAT: I004756), also known as UK 33274, is a medication belonging to the class of quinazoline derivatives. It acts as a selective antagonist of postsynaptic α1-adrenergic receptors. By blocking these receptors, doxazosin relaxes smooth muscles in the prostate, bladder neck, and blood vessels. This leads to the dilation of blood vessels and a reduction in blood pressure, making it useful in the treatment of hypertension (high blood pressure). Additionally, doxazosin is also prescribed for the management of urinary symptoms associated with benign prostatic hyperplasia (enlarged prostate).

Reference

1: Pool JL. Doxazosin: a new approach to hypertension and benign prostatic
hyperplasia. Br J Clin Pract. 1996 Apr-May;50(3):154-63. Review. PubMed PMID:
8733335.

2: Kirby RS. Efficacy of doxazosin in normotensive and hypertensive patients with
benign prostatic hyperplasia. Scand J Urol Nephrol Suppl. 1995;168:29-33. Review.
PubMed PMID: 7541549.

3: Dominiak P. [Doxazosin. A postsynaptic alpha 1-adrenergic receptor blocker in
therapy of hypertension]. Internist (Berl). 1993 Jul;34(7):682-7. Review. German.
PubMed PMID: 8103510.

4: Babamoto KS, Hirokawa WT. Doxazosin: a new alpha 1-adrenergic antagonist. Clin
Pharm. 1992 May;11(5):415-27. Review. PubMed PMID: 1349855.

5: Taylor SH. Efficacy of doxazosin in specific hypertensive patient groups. Am
Heart J. 1991 Jan;121(1 Pt 2):286-92. Review. PubMed PMID: 1824652.

6: Pool JL, Taylor AA, Nelson EB. Review of the effects of doxazosin, a new
selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with
essential hypertension. Am J Med. 1989 Aug 16;87(2A):57S-61S. Review. PubMed
PMID: 2569825.

7: Davey MJ. Pharmacologic basis for the use of doxazosin in the treatment of
essential hypertension. Am J Med. 1989 Aug 16;87(2A):36S-44S. Review. PubMed
PMID: 2569823.

8: Young RA, Brogden RN. Doxazosin. A review of its pharmacodynamic and
pharmacokinetic properties, and therapeutic efficacy in mild or moderate
hypertension. Drugs. 1988 May;35(5):525-41. Review. PubMed PMID: 2899495.